Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Development services for gene and cell therapies is planned to begin first in 2025
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Subscribe To Our Newsletter & Stay Updated
